About this trial
DeLLphi-305 is a Phase 3 clinical trial for people who have extensive-stage small-cell lung cancer. This means they have cancer in both lungs, or that it has spread to other parts of the body. Participants will be randomly assigned to receive the trial drug (tarlatamab) in combination with durvalumab or to receive durvalumab alone. Durvalumab is another type of immunotherapy already approved for use.
Tarlatamab is a type of drug called a bispecific T-cell engager, or BiTE® molecule, that has two key parts: a part that attaches to your T-cells, a type of immune cell, and a part that attaches to the cancer cells. It is designed to help the body’s immune cells find, attach to, and attack cancer cells.
Patient Profile
Extensive Stage Small Cell Lung Cancer (ES SCLC)
Where’s this trial being run?
Beaumont Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | DeLLphi-305 |
|---|---|
| Number: | 24-52 |
| Full Title: | DeLLphi-305: A Ph 3, Randomized, Open-label Trial of Tarlatamab With Durvalumab vs Durvalumab Alone in First-line Extensive-Stage Small Cell Lung Cancer Following Platinum, Etoposide, and Durvalumab |
| Principal Investigator: | Prof. Jarushka Naidoo |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Amgen |
| Recruitment Started: |
Global: June 2024 Ireland: January 2025 |
| Global Recruitment Target: | 550 |
|---|---|
| Ireland Recruitment Target: | 2 |